Atossa Therapeutics, Inc.
ATOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $118,824 | $110,951 | $67,111 | $187,120 |
| - Cash | $71,084 | $88,460 | $110,890 | $136,377 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $47,740 | $22,491 | -$43,779 | $50,743 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$27,604 | -$31,354 | -$27,683 | -$20,498 |
| % Margin | – | – | – | – |
| Net Income | -$25,504 | -$30,094 | -$26,960 | -$20,606 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.2 | -0.24 | -0.21 | -0.18 |
| % Growth | 16.7% | -14.3% | -16.7% | – |
| Operating Cash Flow | -$21,030 | -$20,941 | -$20,760 | -$16,472 |
| Capital Expenditures | -$19 | -$14 | -$27 | -$9 |
| Free Cash Flow | -$21,049 | -$20,955 | -$20,787 | -$16,481 |